Latest Denosumab Stories
THOUSAND OAKS, Calif., Dec. 19 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN), today announced submission of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for denosumab, an investigational RANK Ligand inhibitor.
Amgen (NASDAQ:AMGN) today announced full data results from a non-pivotal Phase 3 head-to-head, double-blind trial comparing bone mineral density (BMD) gains in postmenopausal women with low bone mass who transitioned from weekly oral alendronate (Fosamax(R)) to denosumab versus those who continued alendronate therapy.
Amgen (NASDAQ:AMGN) today announced it will present new data from osteoporosis studies of its investigational therapy, denosumab, at the 2008 American Society of Bone and Mineral Research (ASBMR) Annual Meeting that will be held in Montreal, Sept. 12-16, 2008.
Amgen has announced that the FDA has approved Nplate, the first and only platelet producer for the treatment of thrombocytopenia in splenectomized and non-splenectomized adults with chronic immune thrombocytopenic purpura.
Amgen (NASDAQ: AMGN) today announced findings from the pivotal fracture trial evaluating its RANK Ligand inhibitor, denosumab, in the treatment of postmenopausal osteoporosis.
Amgen has reported positive results from a three-year pivotal Phase III placebo-controlled trial evaluating denosumab in the treatment of bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer.
Amgen (NASDAQ:AMGN) today announced findings from a three-year pivotal Phase 3 placebo-controlled trial evaluating denosumab in the treatment of bone loss in men undergoing androgen deprivation therapy (ADT) for non-metastatic prostate cancer.
Research and Markets (http://www.researchandmarkets.com/reports/c46468) has announced the addition of Espicom Business Intelligence's new report: New Drug Futures: Musculoskeletal Chapter to their offering. Please note this chapter is taken from the "New Drug Futures" report.
Astronauts who travel in space are at risk for bone loss in much the same way that cancer patients who receive radiation therapy are, and both groups are more likely to develop fractures than the general population.
By Deena Beasley LOS ANGELES (Reuters) - Amgen Inc. said on Sunday that early results from mid-stage trials of its experimental drug denosumab show that it works at least as well as current therapies to limit bone loss in patients with late-stage cancer.
- A person in a secondary role, specifically the second most important character (after the protagonist).